Press releases

YearType

2023

13 Dec 2023, 07:00 | Regulatory

Hansa Biopharma Nomination Committee formed

7 Dec 2023, 07:00

Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)

5 Dec 2023, 13:05 | Regulatory

Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables

27 Nov 2023, 07:00 | Regulatory

Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota

26 Oct 2023, 07:00 | Regulatory

Hansa Biopharma Interim Report January-September 2023

•   Encouraging high-level results for first-in-human trial of HNSA-5487
•   Well attended Hansa-sponsored symposium at ESOT focusing on first patient experiences
•   Dr. Hitto Kaufmann appointed new CSO

17 Oct 2023, 07:00

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

11 Oct 2023, 18:35 | Regulatory

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

Biologic License Application submission expected for 2025

9 Oct 2023, 17:35

Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

HNSA-5487 is a next-generation IgG-cleaving enzyme and the lead candidate in the NiceR development program

E-mail

Press releases

2023

Sign up to receive updates on the latest company news and filings

Choose type